For years, venture capitalists who bet the seed money used to start small biotechnology companies have played second fiddle to their colleagues in the tech world, where a bet of a few million dollars on some college dude in a hoodie can rapidly turn into the next Facebook or AirBnB. In biotech–which almost always means drug discovery–the timelines are longer, the costs higher. And that, sadly, often means that the financial returns are lower.
